SynapDX is an early-stage laboratory services company developing blood-based diagnostic tests for the early detection of autism.
SynapDx's mission is to provide laboratory testing services to physicians who evaluate children for developmental disorders with the initial goal of enabling earlier detection of autism. Autism Spectrum Disorders are currently estimated to affect 1 in 110 children in the United States according to the Centers for Disease Control.SynapDx was founded by Stanley Lapidus and closed a Series A round of venture funding in May 2010 from North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners. SynapDx's corporate headquarters is located in Lexington, Massachusetts.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 22, 2013 | Series Unknown | $15.40M | 1 | — | — | Detail |
Feb 21, 2013 | Series C | $2M | 1 | LabCorp | — | Detail |
Nov 12, 2012 | Series B | $6M | 1 | — | — | Detail |
Jun 1, 2010 | Series A | $9M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
LabCorp | — | Series Unknown |
General Catalyst | — | Series B |